Newsletter Tool

Today's Rundown

Moderna, Regeneron warn about the effectiveness of COVID-19 drugs, vaccines against the omicron variant
Owlet pulls baby-monitoring Smart Sock from market after FDA warning
The top 10 healthcare M&A targets in 2022
GlaxoSmithKline poaches Pfizer vax leader Dormitzer after hemorrhaging vaccine R&D talent
Biogen takes another blow as appeal for Tecfidera patent revival falls short
After flunking key trial, Deciphera cuts 140 jobs, halts development of two drugs
Bristol Myers Squibb's next-gen autoimmune med starts high-stakes FDA review amid classwide JAK scrutiny
Hyperfine’s portable MRI nets FDA clearance for deep learning-powered imaging
RAGE against diabetes complications: Novel drug tamps down tissue damage in mice
'What it takes': As Lilly's Alzheimer's drug approaches FDA, launch leader feels 'amplified' sense of excitement
UnitedHealth Group expects at least $317B in revenue for 2022
Federal judge halts CMS' COVID-19 vaccine mandate for healthcare workers in 10 rural states
TG tumbles as FDA still hasn’t found what its looking for in U2 leukemia combo, orders advisory committee
Insilico Medicine begins first human trial of its AI-designed drug for pulmonary fibrosis

Featured Story

Moderna, Regeneron warn about the effectiveness of COVID-19 drugs, vaccines against the omicron variant

By Kevin Dunleavy

As the world assesses the threat posed by the COVID-19 omicron variant, two top companies producing pandemic drugs and vaccines have warned that their current offerings may not be effective against the variant.

Owlet pulls baby-monitoring Smart Sock from market after FDA warning

By Andrea Park

Owlet is no longer selling its Smart Sock vital sign monitors for babies and toddlers after the FDA informed the company that the devices had been improperly brought to market.

The top 10 healthcare M&A targets in 2022

By Heather Landi

Early in 2020, there was a massive pandemic-induced nosedive in merger and acquisitions deals in healthcare. But the industry rapidly rebounded, and the pace accelerated in 2021. In this report, we’ll take you through some companies that could be in the M&A crosshairs during 2022, such as digital pharmacies and health systems.

GlaxoSmithKline poaches Pfizer vax leader Dormitzer after hemorrhaging vaccine R&D talent

By Ben Adams

GlaxoSmithKline has seen a host of vaccine research staffers exit the Big Pharma over the past year, but it’s hoping a big name can get its vaccine business back on track.

Biogen takes another blow as appeal for Tecfidera patent revival falls short

By Fraiser Kansteiner

A U.S. appeals court has declined to resurrect a key patent on Biogen’s once-stalwart multiple sclerosis med Tecfidera, according to court documents filed Tuesday. It’s the latest spot of trouble for the struggling blockbuster, which succumbed to its first generic competitor last summer.

After flunking key trial, Deciphera cuts 140 jobs, halts development of two drugs

By Kevin Dunleavy

A devastating trial flop for its gastrointestinal cancer drug Qinlock has prompted Deciphera to undergo a transformation. The biopharma will cut 140 jobs, reducing its headcount by 35%. Deciphera also will abandon its development of Qinlock and ovarian cancer candidate, rebastinib.

Bristol Myers Squibb's next-gen autoimmune med starts high-stakes FDA review amid classwide JAK scrutiny

By Angus Liu

After the FDA slapped an updated safety warning on marketed oral JAK inhibitors for inflammatory diseases, market watchers have started worrying about other candidates in the pipeline. Bristol Myers Squibb now has a date to learn how the agency views its novel medicine deucravacitinib, with blockbuster sales at stake.

Hyperfine’s portable MRI nets FDA clearance for deep learning-powered imaging

By Conor Hale

The portable MRI machine maker Hyperfine obtained a new clearance from the FDA, adding deep-learning algorithms that can boost the quality of images taken by its scanner-on-wheels.

RAGE against diabetes complications: Novel drug tamps down tissue damage in mice

By Arlene Weintraub

NYU researchers have developed a drug that prevent a protein called rage from triggering inflammatory signals in diabetes. The drug reduced the risk of heart attack and sped up the healing of diabetic wounds in mouse models of diabetes.

'What it takes': As Lilly's Alzheimer's drug approaches FDA, launch leader feels 'amplified' sense of excitement

By Annalee Armstrong

Fierce Biotech profiles three women breaking barriers in Alzheimer's disease R&D at leading pharmaceutical companies. Today, Eli Lilly's donanemab launch leader Brandy Matthews.

UnitedHealth Group expects at least $317B in revenue for 2022

By Paige Minemyer

UnitedHealth will host its annual investor conference Tuesday morning, and the healthcare giant updated its outlook for 2021 ahead of the meeting.

Federal judge halts CMS' COVID-19 vaccine mandate for healthcare workers in 10 rural states

By Dave Muoio

The preliminary injunction is an early win for the 22 rural and red states that have filed challenges against CMS' COVID-19 vaccine requirement for healthcare workers.

TG tumbles as FDA still hasn’t found what its looking for in U2 leukemia combo, orders advisory committee